Ceftriaxone-induced Neurotoxicity in a Patient after Pancreas-Kidney Transplantation

Hideharu Hagiya¹, Koji Miyawaki², Norihisa Yamamoto¹, Hisao Yoshida¹, Akihiro Kitagawa¹, Tadafumi Asaoka³, Hidetoshi Eguchi³, Yukihiro Akeda¹ and Kazunori Tomono¹

Abstract:
Ceftriaxone is a widely used third-generation cephalosporin showing advantageous pharmacokinetic properties and a broad antimicrobial spectrum. We herein report a case of ceftriaxone-induced neurotoxicity in a 56-year-old man on hemodialysis. Seven days after initiating high-dose ceftriaxone, the patient developed impaired consciousness along with facial myoclonus and sporadic phonation. The symptoms clearly disappeared shortly after withdrawal of the drug. Ceftriaxone is considered a safe antibiotic for patients with renal insufficiency, since it is excreted via both haptic and renal pathways. Physicians should note that antibiotic-associated encephalopathy may develop in patients administered ceftriaxone, especially in those complicated with renal dysfunction.

Key words: antibiotic-associated encephalopathy, ceftriaxone, chronic kidney disease, hemodialysis, nonconvulsive status epilepticus, transplantation

Introduction
Ceftriaxone (CTRAX) is a common antibiotic frequently used in both in- and outpatients. The pharmacological advantages of CTRAX include a broad microbial spectrum, long half-life, and good penetration into systemic tissues, including the central nervous system. In contrast to other beta-lactams, CTRAX is metabolized at the liver, and a renal dose adjustment is usually not necessary. In addition, side effects and drug interactions are uncommon. Therefore, it is generally assumed that CTRAX can be safely administered to elderly patients, including those with chronic kidney disease (1).

Following antimicrobial treatments, some patients may develop antibiotic-associated encephalopathy (AAE). Among beta-lactams, cefepime, a fourth-generation cephalosporin, is known to cause encephalopathy, particularly in elderly patients with renal insufficiency (2, 3). According to a previous review, CTRAX is listed as a low-to-medium-risk agent based on its structural characteristics (4, 5); however, CTRAX-associated encephalopathy has rarely been reported. To our knowledge, only 10 such cases have been documented in the literature to date (6-11). In this report, we describe another case of CTRAX-induced neurotoxicity complicated by involuntary facial movements.

Case Report
The patient was a 56-year-old man (dry body weight: 50.5 kg). He had undergone simultaneous pancreas-kidney transplantation five years earlier, but he was on hemodialysis due to graft failure. One day, he was found to have a low blood pressure and decreased oxygen saturation at a hemodialysis clinic and was immediately transferred to our hospital as an emergency case. On admission, he was alert but in a state of shock. He reported pain in his left chest, which was intensified by deep breaths and dry cough. The patient...
was prescribed prednisolone (2.5 mg per day), cyclosporine (120 mg per day), mycophenolate mofetil (500 mg per day), and everolimus (1 mg per day). He had no history of neurological disorders or brain surgery. Laboratory results showed elevated serum C-reactive protein levels (CRP, 21.14 mg/dL). A chest radiograph demonstrated permeability decay in his left lower lung, and computed tomography (CT) of his chest revealed diffuse consolidation in the left lower lobe. The patient was diagnosed with septic shock secondary to pneumonia and pleurisy and was hospitalized at an emergency center. Treatment was started empirically with renal doses of meropenem and levofloxacin.

Three days after hospitalization, the patient was moved to a general ward. Although a bacterial culture of his sputum was unremarkable, antibiotic therapy was switched to CTRX (2 g q12h) and minocycline (100 mg q12h) on day 6. Despite antibiotic treatment, the pleural effusion increased, and he underwent paracentesis of the pleural cavity on day 8. The pleural fluid was clear, and a bacterial culture was negative. Nevertheless, the levels of serum inflammatory markers and his body temperature remained high.

On admission day 13, the patient started to become disoriented and agitated. At that time, he was afebrile, and laboratory data showed the serum CRP level to be 11.1 mg/dL; otherwise, there were no markedly abnormal values. On the same day, continuous air leakage emerged. Chest CT revealed a newly formed pulmonary cavity in the left lower lobe, indicating pulmonary suppuration and a subsequent thoracic empyema. No explanation was found for the patient’s altered consciousness. Throughout the clinical course, the serum levels of total protein and albumin declined to 5.0 and 2.4 g/dL, respectively. A cerebrospinal fluid examination showed normal findings: initial pressure, 16 cmH₂O; cells 1/μL, protein 36 mg/dL, and glucose 67 mg/dL. Therefore, an adverse drug effect remained a potential cause of the impaired consciousness. Throughout the clinical course, the serum level of cyclosporine was closely monitored and maintained in an appropriate range.

On reviewing the patient’s course, a high dose of CTRX was continuously administered for 7 days before the patient fell unconscious (usual dose: 1 to 2 g per 24 h). At this point, CTRX-induced neurotoxicity was suspected. The dosage of CTRX was reduced to 2 g per day on day 18, but the

---

**Figure 1.** Electroencephalogram (EEG). (A) EEG on day 18. The patient manifested impaired consciousness. Generalized moderate-to-high-amplitude epileptiform bursts continued throughout the test. (B) EEG on day 28. Three days after the patient recovered from unconsciousness. The abnormal spikes completely disappeared, and alpha waves emerged mainly at the occipital lobes.
patient’s condition did not improve. Subsequently, CTRX was discontinued and switched for piperacillin/tazobactam (2.25 g q8h) on day 20. Five days after the cessation of treatment with CTRX, the patient recovered completely. He was still slightly febrile (37.6°C), but his general condition and vital signs were stable, and his serum CRP level decreased to 3.5 mg/dL. A follow-up EEG showed no abnormal patterns (Fig. 1B), and no neurological symptoms recurred until his discharge from the hospital. The patient’s clinical course is illustrated in Fig. 2.

**Discussion**

We encountered a case of CTRX-associated neurotoxicity occurring in a patient after pancreas-kidney transplantation. The onset and resolution of the neurological symptoms appeared to be closely related to the initiation and discontinuation of CTRX administration, and the EEG findings were similar to previous cases (6, 9). Although one or more of the other drugs concurrently administered with CTRX (cyclosporine, meropenem, levofloxacin, and minocycline) might have potentially caused the encephalopathy, the influence of any of these drugs seemed unlikely, given the clinical course.

Neurological complications are relatively common after solid organ transplantations, appearing in approximately one-third of such patients (12). Frequent etiologies include immunosuppressive agents (e.g. calcineurin inhibitors), central nervous system infections, and encephalopathy. In particular, the differential diagnosis of neural involvement in the late phase (>6 months) includes viral (Herpes simplex virus, Cytomegalovirus, Epstein-Barr virus, Varicella-zoster virus, and progressive multifocal leukoencephalopathy by JC polyomavirus), fungal (*Cryptococcus neoformans*, *Aspergillus* spp., and Mucor), and parasitic (*Toxoplasma gondii*, *Amebiasis*, *Strongyloides stercoralis*) infections (13). In addition, neoplastic etiologies such as post-transplantation lymphoproliferative disorder should also be considered.

Table summarizes the present and previous cases of CTRX-induced neurotoxicity (6-11). Notably, elderly patients with chronic kidney disease are at particularly high risk for drug-associated encephalopathy. Of the 11 cases, 8 (72.7%) were over 60 years of age. In addition, four had chronic kidney disease, and half of the patients were on either hemodialysis or peritoneal dialysis. Renal insufficiency is in general a common factor for AAE; 25% of all cases of AAE and over 70% of cephalosporin-associated cases have been associated with renal insufficiency (14). A possible reason for the association between renal insufficiency and AAE is impaired biliary excretion in patients with renal dysfunction (5). Impaired biliary excretion may be responsible for the delayed elimination of CTRX, and a subsequently higher serum concentration of the drug can trigger the neurotoxicity.

An excessive dosage can be another predisposing factor for cephalosporin-associated neurotoxicity (15-17). However, the dosages of CTRX administered in the reported cases were mostly normal (≤2 g per day in 8 of 10 adult cases in Table). Thus, the relationship between overdose of the drug and neurotoxicity is uncertain. As few or no reports on the previous CTRX-associated encephalopathy measured the serum concentration of the drug, the association between the serum concentration and neurotoxicity is inconclusive.

Although the pathophysiological mechanisms of cephalosporin-associated neurotoxicity have yet to be fully elucidated, beta-lactam associated encephalopathy is believed to be related to the competitive inhibition of γ-aminobutyric acid in brain tissues (15). CTRX penetrates efficiently into the central nervous system and can trigger increased neural excitability even at normal dosages.

Once recognized, AAE is easily treatable by discontinuing the offending drugs. However, the early diagnosis of CTRX-induced neurotoxicity is challenging for three reasons. First, many clinicians are unaware of this rare adverse effect related to CTRX. Second, the clinical presentations may vary among patients; reported symptoms include altered mental status (6 cases), choreoathetosis (4 cases), and myoclonus (4 cases) (Table). Interestingly, our patient manifested facial...
myoclonus along with sporadic phonation. Third, radiographic and cerebrospinal fluid examinations do not provide any useful information for the diagnosis. Findings based on EEGs, although not specific, may aid in the diagnosis.

Patients’ clinical courses provide the strongest basis for the diagnosis of AAE. The time spans to both the onset and amelioration of AAE have been reported to be 5 days in the median for most offending antibiotics (14). In previous cases of CTRX-induced neurotoxicity, the administration periods before the onset of neurological symptoms were 2 to 6 days, and clinical improvement was seen 1 to 12 days after cessation of the drug (9). In our case, the patient developed neurotoxicity that involved a patient on hemodialysis. Although CTRX is a widely available and potent antibiotic in various clinical settings, clinicians need to be aware that patients with an impaired renal function may not be available. Hemodialysis is ineffective, as CTRX binds well to serum albumin and therefore cannot be removed from the blood (1). As such, discontinuation of the offending drug following an early diagnosis is crucial (14).

In conclusion, this report illustrated a case of CTRX-induced transient encephalopathy that involved a patient on hemodialysis. Although CTRX is a widely available and potent antibiotic in various clinical settings, clinicians need to be aware that patients with an impaired renal function may develop neurotoxicity. The clinical manifestations may be subtle or nonspecific, and therefore, the diagnosis of the adverse event is challenging; however, the early recognition followed by the discontinuation of the causative drug can lead to a rapid recovery. Close observation of a patient’s clinical course can provide essential cues regarding the diagnosis.

Informed consent was obtained from the patient for the publication of this case.

The authors state that they have no Conflict of Interest (COI).

References

12. Marco S, Cecilia F, Patrizia B. Neurologic complications after

---

### Table. Summary of Reported Cases of Ceftriaxone (CTRX)-induced Neurotoxicity.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Sex</th>
<th>Renal function</th>
<th>Dose of CTRX (g/day)</th>
<th>Neurological manifestation</th>
<th>Days to onset</th>
<th>Days to remission</th>
<th>Treatment</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>83</td>
<td>F</td>
<td>CKD</td>
<td>2</td>
<td>Altered mental status, myoclonus</td>
<td>4</td>
<td>5</td>
<td>Discontinue, AED</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>78</td>
<td>F</td>
<td>CKD</td>
<td>2</td>
<td>Altered mental status, myoclonus</td>
<td>6</td>
<td>5</td>
<td>Discontinue, AED</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
<td>F</td>
<td>CKD</td>
<td>2</td>
<td>Altered mental status</td>
<td>4</td>
<td>3</td>
<td>Discontinue</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>80</td>
<td>F</td>
<td>Hemodialysis</td>
<td>4</td>
<td>Choreoathetosis</td>
<td>5</td>
<td>12</td>
<td>Discontinue</td>
<td>8</td>
</tr>
<tr>
<td>5</td>
<td>72</td>
<td>F</td>
<td>Hemodialysis</td>
<td>1</td>
<td>Choreoathetosis</td>
<td>2</td>
<td>1</td>
<td>Discontinue</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>76</td>
<td>M</td>
<td>Hemodialysis</td>
<td>2</td>
<td>Choreoathetosis</td>
<td>6</td>
<td>nd</td>
<td>Discontinue</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>76</td>
<td>M</td>
<td>Hemodialysis</td>
<td>2</td>
<td>Choreoathetosis</td>
<td>5</td>
<td>2</td>
<td>Discontinue</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>65</td>
<td>F</td>
<td>CKD</td>
<td>2</td>
<td>Generalized myoclonic jerks</td>
<td>5</td>
<td>2</td>
<td>Discontinue</td>
<td>9</td>
</tr>
<tr>
<td>9</td>
<td>8</td>
<td>M</td>
<td>Normal</td>
<td>1</td>
<td>Altered mental status</td>
<td>3</td>
<td>3</td>
<td>Discontinue</td>
<td>10</td>
</tr>
<tr>
<td>10</td>
<td>37</td>
<td>F</td>
<td>Peritoneal dialysis</td>
<td>2</td>
<td>Agitation, paraesthesia, visual hallucination</td>
<td>3</td>
<td>1.5</td>
<td>Discontinue</td>
<td>11</td>
</tr>
<tr>
<td>11</td>
<td>56</td>
<td>M</td>
<td>Hemodialysis</td>
<td>4</td>
<td>Altered mental status, Facial myoclonus, sporadic phonation</td>
<td>7</td>
<td>5</td>
<td>Discontinue, Present case</td>
<td></td>
</tr>
</tbody>
</table>


The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2017 The Japanese Society of Internal Medicine

Intern Med 56: 3103-3107, 2017